2023 | Design, synthesis, and biological evaluation of novel HSP27 inhibitors to sensitize lung cancer cells to clinically available anticancer agents | 권영주; 이윤실; 황수연; 전슬기 | Article |
2023 | Di-indenopyridines as topoisomerase II-selective anticancer agents: Design, synthesis, and structure–activity relationships | 권영주; 황수연; 박서정 | Article |
2021 | Discovery of a 2,4-diphenyl-5,6-dihydrobenzo(h)quinolin-8-amine derivative as a novel DNA intercalating topoisomerase IIα poison | 권영주; 전경화; 황수연 | Article |
2021 | Drug-like small molecule HSP27 functional inhibitor sensitizes lung cancer cells to gefitinib or cisplatin by inducing altered cross-linked Hsp27 dimers | 이화정; 권영주; 이윤실; 이재옥; 황수연 | Article |
2022 | Identification of new halogen-containing 2,4-diphenyl indenopyridin-5-one derivative as a boosting agent for the anticancer responses of clinically available topoisomerase inhibitors | 권영주; 전경화 | Article |
2023 | Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers | 이화정; 권영주; 전경화; 황수연; 박서정 | Article |
2019 | Recent therapeutic trends and promising targets in triple negative breast cancer | 권영주 | Review |
2022 | Topoisomerase IIα inhibitory and antiproliferative activity of dihydroxylated 2,6-diphenyl-4-fluorophenylpyridines: Design, synthesis, and structure-activity relationships | 권영주; 황수연 | Article |